Liver Fat Lowered by Ezetimibe-Statin Combination Liver Fat Lowered by Ezetimibe-Statin Combination
A significant 5.8% decrease in hepatic steatosis was seen after 24 weeks ’ treatment with ezetimibe and rosuvastatin comparing baseline with end of treatment values.MDedge News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 30, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Ezetimibe Plus Statin: Attractive Bypass to High-Dose Monotherapy Ezetimibe Plus Statin: Attractive Bypass to High-Dose Monotherapy
Early initiation of this approach should be considered in patients with challenging lipid disorders who are at increased risk of atherosclerotic cardiovascular disease events, observers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2022 Category: Consumer Health News Tags: Cardiology News Source Type: news

Panel Addresses Ezetimibe, PCSK9 Inhibitors for Reducing CV Events
THURSDAY, May 5, 2022 -- In a clinical practice guideline published online May 4 in The BMJ, risk-stratified recommendations are presented for whether another lipid-lowering drug should be added among adults with low-density lipoprotein (LDL)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2022 Category: Pharmaceuticals Source Type: news

Lipid-Lowering Drug Therapy: A Critical Approach Lipid-Lowering Drug Therapy: A Critical Approach
This review summarizes the main characteristics of statins, ezetimibe, and PCSK9 inhibitors as well as emerging lipid-lowering therapies which will further expand the available armamentarium.American Journal of Cardiovascular Drugs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 4, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Kaiser sues big drugmakers around delayed generics for blockbuster cholesterol drugs
The suit centers on Merck's drugs Zetia and Vytorin. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 28, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Kaiser sues big drugmakers around delayed generics for blockbuster cholesterol drugs
The suit centers on Merck's drugs Zetia and Vytorin. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 28, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

EAS Lipid Guidance: Start High-risk Patients on Combo Drug EAS Lipid Guidance: Start High-risk Patients on Combo Drug
Instead of spending time starting very-high-risk patients unlikely to reach goal on a statin alone, clinicians should immediately reach for combination statin-ezetimibe therapy, say European experts.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 29, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

NICE recommends bempedoic acid/ezetimibe for hypercholesterolaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

First new oral treatment for high cholesterol in a decade approved by NICE
Bempedoic acid has been approved for routine NHS prescribing with ezetimibe to treat primary hypercholesterolaemia or mixed dyslipidaemia when statins are unsuitable. (Source: GP Online News)
Source: GP Online News - April 28, 2021 Category: Primary Care Tags: Clinical News Source Type: news

Roszet (Rosuvastatin and Ezetimibe Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Roszet (rosuvastatin and ezetimibe) to Reduce LDL-C in Hyperlipidemia and Homozygous Familial Hypercholesterolemia
Morristown, N.J. March 31, 2021 -- Althera Pharmaceuticals, a company focused on heart health, today announced the FDA approval of Roszet (rosuvastatin and ezetimibe) tablets, as an adjunct to diet, for treatment of elevated low-density lipoprotein... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 31, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Althera ’s Roszet (rosuvastatin and ezetimibe) Tablets, a...
Roszet® is indicated for adults with Primary Non-familial Hyperlipidemia and Homozygous Familial Hypercholesterolemia - Roszet is a powerful and affordable way to significantly lower patients’...(PRWeb March 31, 2021)Read the full story at https://www.prweb.com/releases/fda_approves_altheras_roszet_rosuvastatin_and_ezetimibe_tablets_a_new_oral_therapy_for_powerful_cholesterol_reduction/prweb17832549.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 31, 2021 Category: Pharmaceuticals Source Type: news

Nexlizet (Bempedoic acid and Ezetimibe Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 22, 2021 Category: Drugs & Pharmacology Source Type: news

Nexlizet (Bempedoic acid and Ezetimibe Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 4, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Bempedoic Acid-Ezetimibe Combo for ASCVD, HeFH FDA Approves Bempedoic Acid-Ezetimibe Combo for ASCVD, HeFH
The pairing of two LDL-C-lowering agents called Nexlizet is indicated for use on top of statins to help adults with established ASCVD or heterozygous familial hypercholesterolemia reach their goals.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 27, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news